Print Page  Close Window

News Release

Emergent BioSolutions to Participate in March 2010 Investor Conferences
ROCKVILLE, Md., Feb 22, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be participating in the following investor conferences during March 2010.

  • The RBC Capital Markets Healthcare Conference
    New York, NY
    March 2, 2010
    Biodefense Panel Discussion
    3:35 PM Eastern
    [This will be an audio-only webcast.]
  • The Cowen & Company 30th Annual Healthcare Conference
    Boston, MA
    March 8, 2010
    Corporate Overview Presentation
    1:45 PM Eastern
    [There will be a full webcast with slides that will include discussion of the Company's business activities, financial outlook and current news.]

Both webcasts will be accessible from the Emergent website under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
Media Contact:
Tracey Schmitt
Director, Corporate Communications